Sardar Partha, Kundu Amartya, Nairooz Ramez, Chatterjee Saurav, Ledley Gary S, Aronow Wilbert S
Department of Medicine, New York Medical College, Valhalla, NY, USA,
Curr Cardiol Rep. 2015 Feb;17(2):1. doi: 10.1007/s11886-014-0551-y.
A disparity between evidence and practice in the management of ischemic heart disease is frequently observed. Guideline adherence and clinical outcomes are influenced by system, provider, and patient factors. Recently, performance improvement measures for cardiovascular disease have gained a lot of popularity worldwide. These measures may facilitate the uptake of evidence-based recommendations and improve patient outcomes. While apparently valid as quality metrics, their impacts on clinical outcomes remain limited and are areas of further research. Several methods for optimizing performance have been instituted and essentially involve three different approaches—improvement in the reporting of data on guideline adherence, providing infrastructure and tools, and providing incentives to improve guideline adherence. Public reporting of quality metrics and "pay-for-performance" are some novel performance improvement tools. The impact of these approaches on patient outcomes will be pivotal in improving cardiovascular outcomes in the future.
在缺血性心脏病管理方面,证据与实践之间的差异屡见不鲜。指南的遵循情况以及临床结果受到系统、医疗服务提供者和患者因素的影响。近年来,心血管疾病的绩效改进措施在全球范围内颇受欢迎。这些措施可能有助于采用基于证据的建议并改善患者预后。虽然作为质量指标看似有效,但其对临床结果的影响仍然有限,仍是有待进一步研究的领域。已经制定了几种优化绩效的方法,主要涉及三种不同的途径——改进指南遵循情况的数据报告、提供基础设施和工具,以及提供激励措施以提高对指南的遵循度。质量指标的公开报告和“按绩效付费”是一些新颖的绩效改进工具。这些方法对患者预后的影响对于未来改善心血管疾病预后至关重要。